Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

NCT06669143 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

NCT06033820 ·Status: RECRUITING ·Phase: PHASE2

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

NCT06553352 ·Status: RECRUITING ·Phase: PHASE2

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05797948 ·Status: UNKNOWN ·Phase: NA

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

NCT05846750 ·Status: RECRUITING ·Phase: PHASE2

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

NCT05504603 ·Status: UNKNOWN ·Phase: PHASE2

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

NCT06592170 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

NCT06504940 ·Status: RECRUITING ·Phase: PHASE2

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

NCT06492837 ·Status: RECRUITING ·Phase: PHASE2

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT06427213 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

NCT05635162 ·Status: RECRUITING ·Phase: PHASE2

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

NCT07165769 ·Status: RECRUITING ·Phase: PHASE2

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

NCT06504199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

NCT06793189 ·Status: RECRUITING ·Phase: PHASE2

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

NCT07299331 ·Status: NOT_YET_RECRUITING ·Phase: NA

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

NCT06503263 ·Status: RECRUITING ·Phase: PHASE2

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

NCT06549335 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

NCT06478472 ·Status: RECRUITING ·Phase: NA

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

NCT05596097 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970 ·Status: COMPLETED ·Phase: PHASE2

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

NCT01980628 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT06136351 ·Status: RECRUITING ·Phase: PHASE2

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT06554600 ·Status: RECRUITING ·Phase: PHASE2